<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The aim of the present study was to investigate the effects of sabiporide, a potent and selective NHE1 inhibitor, on <z:e sem="disease" ids="C0151744" disease_type="Disease or Syndrome" abbrv="IHD">myocardial ischemia</z:e>-induced <z:hpo ids='HP_0011675'>arrhythmias</z:hpo> and <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo> and the possible pathways related to the cardioprotection afforded by sabiporide treatment </plain></SENT>
<SENT sid="1" pm="."><plain>Anesthetized rats were subjected to <z:e sem="disease" ids="C0151744" disease_type="Disease or Syndrome" abbrv="IHD">myocardial ischemia</z:e> via left main coronary <z:mp ids='MP_0006134'>artery occlusion</z:mp> for 30 minutes, followed by 2 hours of reperfusion </plain></SENT>
<SENT sid="2" pm="."><plain>Administration of sabiporide (0.01-3.0 mg/kg) prior to coronary <z:mp ids='MP_0006134'>artery occlusion</z:mp> dose-dependently reduced <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-induced <z:hpo ids='HP_0011675'>arrhythmias</z:hpo> and <z:mpath ids='MPATH_124'>infarct</z:mpath> size with an ED50 value of 0.14 mg/kg </plain></SENT>
<SENT sid="3" pm="."><plain>Administration of sabiporide (1.0 mg/kg) prior to reperfusion also reduced <z:mpath ids='MPATH_124'>infarct</z:mpath> size by 38.6% </plain></SENT>
<SENT sid="4" pm="."><plain>The reduction in <z:mpath ids='MPATH_124'>infarct</z:mpath> size was accompanied by a decrease in circulating levels of <z:chebi fb="2" ids="16919">creatine</z:chebi> phosphokinase and troponin I </plain></SENT>
<SENT sid="5" pm="."><plain>In addition, sabiporide (1.0 mg/kg) given prior to coronary <z:mp ids='MP_0006134'>artery occlusion</z:mp> or immediately before reperfusion significantly reduced phosphorylation of the extracellular signal-regulated kinase (ERK1/2) and the expression of the inducible nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> synthase (iNOS) following <z:e sem="disease" ids="C0151744" disease_type="Disease or Syndrome" abbrv="IHD">myocardial ischemia</z:e>-reperfusion </plain></SENT>
<SENT sid="6" pm="."><plain>This study demonstrates that sabiporide is a potent and effective cardioprotective agent during <z:e sem="disease" ids="C0151744" disease_type="Disease or Syndrome" abbrv="IHD">myocardial ischemia</z:e> and reperfusion, by reducing serious <z:hpo ids='HP_0004308'>ventricular arrhythmias</z:hpo> and myocardial <z:mpath ids='MPATH_124'>infarct</z:mpath> size </plain></SENT>
<SENT sid="7" pm="."><plain>The cardioprotection afforded by sabiporide is attributed in part to inhibition of ERK1/2 phosphorylation and suppression of iNOS expression </plain></SENT>
</text></document>